Investors are looking for the next Teladoc Health (NYSE: TDOC). By that, I mean a company with triple-digit (111%, in Teladoc's case) revenue growth that's showing up in the stock price -- Teladoc delivered a 139% gain last year -- and that promises more growth to come. Chinese telemedicine company 111 (NASDAQ: YI) hopes to fit that bill.
It's off to a good start. The latest earnings report shows triple-digit (113%) revenue growth. And as the first Chinese telemedicine player listed in the U.S., the stock has soared by more than 200% since the start of the year. But can 111 truly keep up that pace and ensure its position as the next telemedicine winner?
Image source: Getty Images.
Source Fool.com